In support of the potential impact of redox metabolic profiling on clinical outcome, we observed that AML patients with an elevated percentage of GSHhi MITOhi CD34+ cells, homogenously treated with conventional chemotherapy, experienced poor clinical outcomes (log-rank p = 0.04) (Supplementary: Fig. 1i, j). This evidence concerns the gene CD34 and acute myeloid leukemia.